General Information of Drug (ID: DM75RFJ)

Drug Name
Siplizumab Drug Info
Synonyms Siplizumab (USAN/INN)
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 2 [1]
Psoriasis vulgaris EA90 Discontinued in Phase 2 [2]
Cross-matching ID
TTD Drug ID
DM75RFJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [3]
Cyclo(1,12)PenIYDTKGKNVLC-OH DMVDS8B Discovery agent N.A. Investigative [4]
Pen(Acm)AQFRKEKETFC(Acm)-OH DM81AWU Discovery agent N.A. Investigative [4]
Cyclo(1,11)H-ESIYDPGDDIK-OH DM4A1TF Discovery agent N.A. Investigative [5]
Cyclo(1,10)H-EIYDPGDDIK-OH DM5CBQ9 Discovery agent N.A. Investigative [5]
Cyclo(1,10)EIYDPGDDIK DMFUG05 Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell surface antigen CD2 (CD2) TTJDUNO CD2_HUMAN Not Available [2]

References

1 Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.Int J Dermatol. 2010 Jul;49(7):818-28.
2 Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52.
3 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4 Structure-activity studies of peptides from the "hot-spot" region of human CD2 protein: development of peptides for immunomodulation. J Med Chem. 2005 Oct 6;48(20):6236-49.
5 Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. J Med Chem. 2009 Feb 12;52(3):726-36.